Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 8/20 | 0.49 |
| ▸ | MMP9 | P14780 | 8/20 | 0.49 |
| ▸ | MMP8 | P22894 | 8/20 | 0.49 |
| ▸ | MMP13 | P45452 | 8/20 | 0.49 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | BMP1 | P13497 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11888704 | 0.90 | MMP2 (0.46) | MMP2MMP9MMP8MMP13CXCR3 | |
| SCHEMBL5459830 | 0.84 | MMP2 (0.48) | MMP2MMP9MMP8MMP13CXCR3 | |
| SCHEMBL11956143 | 0.83 | BMP1 (0.54) | MMP2MMP9MMP8MMP13CXCR3 | |
| SCHEMBL5463131 | 0.83 | BMP1 (0.54) | MMP2MMP9MMP8MMP13CXCR3 | |
| SCHEMBL5451163 | 0.82 | TAS2R14 (0.64) | MMP2MMP9MMP8MMP13CXCR3 | |
| SCHEMBL5469172 | 0.80 | HPGD (0.44) | MMP2MMP9MMP8MMP13CXCR3 | |
| SCHEMBL11888705 | 0.80 | MMP2 (0.44) | MMP2MMP9MMP8MMP13CXCR3 | |
| SCHEMBL7089280 | 0.79 | MMP2 (0.59) | MMP2MMP9MMP8MMP13CXCR3 | |
| SCHEMBL7089279 | 0.79 | MMP2 (0.59) | MMP2MMP9MMP8MMP13CXCR3 | |
| SCHEMBL11956305 | 0.78 | ACHE (0.38) | HPGDOPRK1OPRM1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8231858-B2 | Diagnostic imaging agents with MMP inhibitory activity | GE HEALTHCARE LIMITED (GB) | 2012-07-31 | — | — | US | disclosed |
| US-20070071670-A1 | Diagnostic imaging agents with mmp inhibitory activity | GE HEALTHCARE LIMITED (GB) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070071670-A1 | Diagnostic imaging agents with mmp inhibitory activity | MMP1, MMP3, MMP7 | MMP2 15/4885MMP9 8/4885MMP8 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.